Table 5.
Risk factors associated with side effects in the Algerian population.
| Variable | Local Side Effects | Systemic Side Effects | Total Side Effects | ||||
|---|---|---|---|---|---|---|---|
| Number (%) | Sig. | Number (%) | Sig. | Number (%) | Sig. | ||
| Age | 18–30 years old | 39 (60) | 0.574 | 37 (56.9) | 0.160 | 44 (67.7) | 0.124 |
| 31–40 years old | 32 (59.3) | 0.532 | 36 (66.7) | 0.604 | 39 (72.2) | 0.653 | |
| 41–50 years old | 29 (69) | 0.341 | 25 (59.5) | 0.518 | 32 (76.2) | 0.775 | |
| Over 50 years old | 23 (65.7) | 0.689 | 27 (77.1) | 0.036 | 31 (88.6) | 0.114 | |
| Sex | Male | 53 (54.6) | 0.02 | 52 (53.6) | 0.003 | 65 (67) | 0.017 |
| Female | 70 (70.7) | 73 (73.7) | 81 (81.8) | ||||
| ABO group | A | 37 (61.7) | 0.703 | 40 (66.7) | 0.528 | 45 (75) | 0.869 |
| AB | 10 (62.5) | 1 | 10 (62.5) | 1 | 11 (68.8) | 0.563 | |
| B | 27 (71.1) | 0.245 | 27 (71.1) | 0.275 | 31 (81.6) | 0.304 | |
| O | 48 (60) | 0.486 | 46 (57.5) | 0.153 | 57 (71.3) | 0.427 | |
| BMI class | Normal | 52 (56.5) | 0.090 | 54 (58.7) | 0.164 | 61 (66.3) | 0.013 |
| Obese | 47 (64.4) | 0.716 | 46 (63) | 0.864 | 58 (79.5) | 0.220 | |
| Overly obese | 24 (77.4) | 0.072 | 25 (80.6) | 0.041 | 27 (87.1) | 0.114 | |
| Chronic diseases | Yes | 32 (72.7) | 0.12 | 34 (77.3) | 0.034 | 39 (88.6) | 0.015 |
| No | 91 (59.9) | 91 (59.9) | 107 (70.4) | ||||
| Allergy | Yes | 49 (67.1) | 0.33 | 50 (68.5) | 0.290 | 57 (78.1) | 0.374 |
| No | 74 (60.2) | 75 (61) | 89 (72.4) | ||||
| Smoking | Yes | 19 (59.4) | 0.665 | 18 (56.3) | 0.333 | 21 (65.6) | 0.374 |
| No | 104 (63.4) | 107 (65.2) | 125 (76.2) | ||||
| Medication | Yes | 74 (77.1) | 0.000 | 67 (69.8) | 0.086 | 80 (83.3) | 0.005 |
| No | 49 (49) | 58 (58) | 66 (66) | ||||
| COVID-19 infection | Yes | 71 (58.7) | 0.134 | 77 (63.6) | 0.959 | 88 (73.8) | 0.707 |
| No | 52 (69.3) | 48 (64) | 58 (76.4) | ||||
| Booster type | Adenoviral-virus | 79 (77.5) | 0.000 | 77 (75.5) | 0.000 | 89 (87.3) | 0.000 |
| Inactivated-virus | 44 (46.8) | 48 (51.1) | 57 (60.6) | ||||
| Mixing/matching (primers-booster) | AA + | 43 (79.6) | 0.003 | 40 (74.1) | 0.064 | 50 (92.6) | 0.000 |
| AI + | 11 (47.8) | 0.115 | 11 (47.8) | 0.09 | 13 (56.5) | 0.035 | |
| IA + | 38 (74.5) | 0.044 | 39 (76.5) | 0.028 | 40 (81.6) | 0.256 | |
| II + | 31 (45.6) | 0.000 | 35 (51.5) | 0.009 | 43 (61.4) | 0.002 | |
| Time between primers and booster doses (months) | 1 month or less | 11 (57.9) | 0.619 | 12 (63.2) | 1.000 | 14 (73.7) | 1 |
| 1 to 3 months | 19 (57.6) | 0.472 | 19 (57.6) | 0.431 | 21 (63.6) | 0.122 | |
| 3 to 6 months | 64 (69.6) | 0.076 | 62 (67.4) | 0.297 | 74 (80.4) | 0.066 | |
| More than 6 mths | 29 (56.9) | 0.285 | 31 (60.8) | 0.628 | 36 (70.6) | 0.473 | |
Chi-squared (χ2) test was used with a significance level (sig.) of 0.05. Bold character refers to statistically significant values. + A: adenoviral-based vaccine, I: inactivated-virus vaccine.